Condition: Hepatocellular Carcinoma · Immunotherapy · CAR · Sponsor: Second Affiliated Hospital of Guangzhou Medical University
The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test the anti-cancer function by the GPC3/TGFβ-CAR-T cells in human HCC patients with GPC3 expression. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/TGFβ-CAR-T cell immunotherapy on human will firstly be tested.
This description comes directly from the study's public registry record.
Zhenfeng Zhang, MD,PhD · 0086-020-34153532 · zhangzhf@gzhmu.edu.cn
Peng Li, PhD · +86 20 32015300 · lipeng@invivobio.com.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03198546